Posted by Michael Wonder on 03 Jul 2024
China’s National Medical Products Administration Approves Xtandi (enzalutamide) in metastatic hormone sensitive prostate cancer
2 July 2024 - Approval marks Xtandi’s third indication for advanced prostate cancer in China.
Astellas today announced that the Center for Drug Evaluation of the China National Medical Products Administration has approved Xtandi (enzalutamide) for the treatment of patients with metastatic hormone sensitive prostate cancer.
